Nervonik closes oversubscribed $52.5M Series B for ECAP-sensing peripheral nerve stimulation — total exceeds $65M
Summary
Nervonik announced the closing of an oversubscribed $52.5 million Series B financing on April 27, 2026, led by Amzak Health with Elevage Medical Technologies, U.S. Venture Partners, Lumira Ventures, Foothill Ventures, and Shangbay Capital. Total funding now exceeds $65M following a $13M Series A in March 2025. Nervonik's PNS system is fundamentally differentiated by integrating ECAP recording and real-time physiological sensing into implantable leads — the same ECAP measurement approach that Saluda Medical proved superior for SCS — enabling personalized closed-loop therapy that adapts based on nerve response rather than fixed stimulation parameters. First-in-human clinical study was completed in 2024.
Why it matters
Nervonik applying ECAP-based closed-loop technology to peripheral nerve stimulation is the direct translation of Saluda Medical's SCS success to a new anatomical target. If ECAP-guided PNS demonstrates superiority over conventional PNS for chronic pain as Evoke did for SCS, Nervonik would own the same differentiation in the rapidly growing peripheral nerve stimulation market. Amzak Health leading reflects their thesis that intelligent sensing is the next wave in neuromodulation.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial